IGF-1 LR3 — 2 mg
IGF-1 LR3 is an engineered 83-amino-acid analog of human IGF-1 with reduced IGFBP binding and extended stability. Supplied as a 2 mg lyophilised vial for laboratory research and analytical use only. Not for human or veterinary administration.
€ 39.00
Description
IGF-1 LR3 2 mg — Sterling Knight Pharmaceuticals
Category: Peptide / Growth Factor Research Compound
Brand: Sterling Knight Pharmaceuticals
Strength: 2 mg (lyophilised)
Form: Sterile peptide vial for reconstitution
Packing: 1 × vial
Origin: United Kingdom
Price: €39
Research Use: For laboratory, analytical and in-vitro work only. Not for human or veterinary use.
🧬 What Is IGF-1 LR3?
IGF-1 LR3 (Long R3 Insulin-Like Growth Factor-1) is a modified recombinant analog of human IGF-1 engineered for increased bioavailability and reduced binding to IGF-binding proteins (IGFBPs).
It contains:
- A substitution of Arg → Glu at position 3
- A 13-amino-acid N-terminal extension
- Total length: 83 amino acids
- Molecular weight: ~9.1 kDa
These changes preserve IGF-1 receptor agonism while greatly improving stability and potency relative to native IGF-1.
🔬 Key Research Highlights
1. Reduced IGFBP Binding
Native IGF-1 binds strongly to IGFBPs, limiting activity in cell-culture systems. IGF-1 LR3 shows significantly lower IGFBP affinity, resulting in:
- Higher free fraction
- Greater receptor availability
- Enhanced potency in vitro
2. Extended Half-Life
Literature reports half-life ranges from 20–30 hours to 56–72 hours, depending on experimental matrix and method. This enables more sustained IGF-1 pathway activation in culture models.
3. Proven Utility in Cell-Culture Systems
- Improves survival in low-serum and serum-free environments
- Promotes proliferation in IGF-dependent lines
- Often more effective than insulin or IGF-1
4. Anti-Doping Relevance
IGF-1 and analogs, including LR3, are prohibited under WADA S2 (Peptide hormones, growth factors, related substances and mimetics).
📚 Research Applications
- IGF-1 receptor signalling models
- Protein synthesis and cell-growth assays
- PK/PD comparison of IGF-1 analog stability
- Method development for LC-MS/MS anti-doping detection
- Cell-culture optimisation in reduced-serum environments
⚠️ Potential Risks & Class-Based Considerations
IGF-axis activation influences glucose handling, mitogenic pathways and cellular proliferation. Risks depend on model, concentration and exposure duration.
- May alter glucose uptake and insulin signalling
- May stimulate mitogenic/anti-apoptotic pathways
- Listed as a prohibited peptide under WADA S2
Handle as a bioactive peptide using appropriate PPE, SDS documentation and institutional biosafety protocols.
🛑 Compliance & Legal Notice
- FOR RESEARCH USE ONLY – Not for human consumption
- Not a medicine, supplement, or veterinary preparation
- Not intended for performance enhancement
- Must be used only by qualified personnel under laboratory SOPs
- WADA Category: S2 – Peptide hormones, growth factors, and mimetics
📊 Technical Data Table
| Field | Data |
|---|---|
| Chemical Name | Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3) |
| Synonyms | Long R3 IGF-1, LR3-IGF-I, Long Arg3 IGF-1 |
| Chemical Formula | C400H619N111O115S9 |
| Molecular Weight | ≈ 9,111 Da |
| CAS Number | 143045-27-6 (common listing) |
| Protein Length | 83 amino acids |
| Total Content | 2 mg lyophilised peptide |
| Stability | Up to 36 months when stored per label |
| Origin | United Kingdom |
| Intended Use | Laboratory / analytical / in-vitro research only |
Research chemical — not for human or veterinary use.
There are no reviews yet.
